RxDoctor Payments Data

Jeremy Wittenborn, MD

Nephrology · Indianapolis, INNPI 1255340691

Payments from drug & device makers

$2,980in general payments, 2019–2025

Across 149 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$775
  • Otsuka America Pharmaceutical, Inc.$479
  • Amgen$367
  • Novartis$338
  • Bayer$151
  • Calliditas Therapeutics US Inc.$136
  • plus $735 from 15 others

What the payments were for

  • Food & beverage$2,75092%
  • Education$2308%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,980 in reported general payments places this provider in the 70th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$156,308
Medicare patients
343
Services billed
1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$89,808
FarxigaDapagliflozin Propanediol125$85,230
AuryxiaFerric Citrate25$62,712
VelphoroSucroferric Oxyhydroxide16$39,234
XphozahTenapanor Hcl13$36,195
KerendiaFinerenone19$17,331
Sevelamer Carbonate27$14,779
OzempicSemaglutide11$10,500
Torsemide144$3,738
Potassium Citrate ErPotassium Citrate11$1,671
Chlorthalidone91$1,286
Valsartan50$968
Tramadol Hcl29$933
Gabapentin33$857
Losartan Potassium94$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$89,80893 claims
AstraZenecaFarxiga$775$85,230125 claims
Akebia Therapeutics IncAuryxia$110$62,71225 claims
Fresenius USA Marketing, Inc.Velphoro$105$39,23416 claims
BayerKerendia$151$17,33119 claims
Novo NordiskOzempic$30$10,50011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 238 nephrology providers in Indiana.

Other nephrology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →